News

   

Destiny Pharma’s SAB Member Professor Dale Gerding is Keynote Speaker at C. diff. International Conference

Brighton, United Kingdom – 4th November 2021 – Destiny…

Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference

VMB-100 shows therapeutic potential in Stress Urinary Incontinence …

Phebra Acquires Equity Stake in UK Specialty Hospital Pharma Company Flexipharm Austrading

- Phebra takes part ownership of Flexipharm Austrading through…

Verona Pharma Announces November 2021 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona…

Muna Therapeutics appoints Dr. Niels Plath as Chief Scientific Officer

Brings more than 15 years of CNS drug discovery and development…

Arix Bioscience: Aura Biosciences prices Nasdaq IPO

LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, "Arix"),…

eTheRNA immunotherapies conference attendance for November 2021

eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage…

Futura Medical plc Board Appointment

Futura Medical plc (AIM: FUM), a pharmaceutical company developing…

Synendos Therapeutics Appoints Scientific Advisory Board

Synendos Therapeutics is thrilled to announce the formation of…

Synendos Therapeutics Appoints Scientific Advisory Board

Synendos Therapeutics is thrilled to announce the formation of…

The DayOne Digital Health Accelerator Program

DayOne focus on healthcare innovation driven by digital health…

Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies

London, UK – 21 October 2021 - Leucid Bio (“Leucid” or…

ONA Therapeutics Strengthens Scientific Leadership Team

Industry veteran in oncology antibody discovery & development…

Novo Holdings Leads US$21M Series A Financing in BI-OMILQ

Funds will be used to support the development of pioneering…

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

October 18, 2021 Early data from Phase 1/2 clinical trial…

Pyxis Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis…

Arix Bioscience plc Business Update and Cancellation of Share Buyback

LONDON, 18 October 2021: Arix Bioscience plc (“Arix” or the…

Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus

Major US hospital-based clinical trial highlights benefit of…

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

ALAMEDA, Calif. & CAMBRIDGE, UK – October 14, 2021 – Exelixis,…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

Get in touch
© Optimum Strategic Communications.